A Phase 1 interventional study of Carfilzomib and Lenalidomide in Relapsed Multiple Myeloma, sponsored by Amgen. Completed at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-30.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.
Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 31st largest by enrollment, is one of 2 that started in 2008, is one of 17 in phase 1, and was the 5th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Natalie Callander · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Australia, Brazil and 5 more countries
Ages 18+
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
By country, each count listing its studies:
carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 78 · Phase 3 15 · Phase 4 2
First in 2005; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 54 across the 113 interventional studies. Of the 67 that completed or were terminated, 46 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 113 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
43 studies in Multiple Myeloma by Amgen: none open now, none under way, none of them phase 3. Of 41 finished, 36 (88%) have results posted.
Among the 43 studies in Multiple Myeloma by Amgen, this one is the 23rd largest by enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2008, is one of 13 in phase 1, and was the 9th registered.
Amgen’s Multiple Myeloma studies by the year they started, since 2005.
18 of the studies testing carfilzomib in Multiple Myeloma that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT04096066Phase 3Fondazione EMN Italy OnlusA Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | 2027-09-01 |
| NCT02659293Phase 3University of ChicagoTrial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | 2027-11 |
| NCT04973605BeOne MedicinesA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | 2026-11 |
| NCT04883242University of WashingtonIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | 2026-12-31 |
Add all 18 to your calendar (.ics) → With an account.
Among the 113 studies testing carfilzomib in Multiple Myeloma, from their registry updates:
Among Amgen’s 43 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and maximum tolerated dose (MTD) of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Disease related:
, as indicated by one or more of the following:
Prior to enrollment, sites must provide evidence of myeloma progression/relapse, with start and stop dates of the most recent treatment regimen, as well as best tumor response to all prior treatment regimens.
Demographic
(ECOG) Performance Status 0-2
Laboratory
(ANC) ≥ 1,000/mm³, ≥ 8 gm/dL, count ≥ 50,000/ mm³ (≥ 30 × 10\^9/L if myeloma involvement in the bone marrow is > 50%)
Calculated or measured of ≥ 50 mL/minute, calculated using the formula of Cockcroft and Gault [(140 - Age) x Mass (kg) / (72 x creatinine mg/dL)]; multiply result by 0.85 (if female). Other generally accepted calculation methods can be substituted.
Ethical/Other
Exclusion Criteria:
Disease related
Participation in an therapeutic study within 3 weeks or within 5 drug half-lives (t1/2) prior to first dose, whichever time is greater.
Concurrent conditions
Non-hematologic within the past three years except
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment during Cycles 1 through 12 consisted of carfilzomib (15, 20, or 20/27 mg/m²) on Days 1, 2, 8, 9, 15, and 16; lenalidomide (10, 15, 20, or 25 mg) on Days 1 to 21; and low-dose dexamethasone (40 mg) given 30 minutes to 4 hours before the carfilzomib dose on Days 1, 8, and 15, as well as on Day 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
Drug: Carfilzomib · Drug: Lenalidomide · Drug: Dexamethasone
Carfilzomib for Injection was administered intravenously over 10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for the first 12 cycles. Each dose of Carfilzomib for Injection was normalized to body surface area.
Also known as: Kyprolis®
Lenalidomide was administered orally on Days 1 to 21 of each 28-day cycle.
Also known as: REVLIMID®
Dexamethasone 40 mg orally or intravenous equivalent was administered 30 minutes to 4 hours before carfilzomib on Days 1, 8, and 15, as well as on Day 22 of each 28-day cycle.
Number of Participants With Adverse Events (AEs)
Treatment-related are those AEs with possible or probable relationship to carfilzomib, lenalidomide or dexamethasone as assessed by the Investigator. The severity of each adverse event was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0, per the following: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Serious adverse events were defined as AEs meeting one of the following: death, life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect in the offspring of an exposed participant, important medical events that may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above, or pregnancy or suspected pregnancy.
Time frame: From the first dose of study drug until 30 days after the last dose; 1 to 52 months, with an average of 12 months.
Number of Participants With Dose-limiting Toxicities
Dose-limiting toxicity was defined as any of the following events assessed as related to carfilzomib, lenalidomide, or dexamethasone: Nonhematologic * ≥ Grade 2 neuropathy with pain * ≥ Grade 3 nonhematologic toxicity (excluding nausea, vomiting, diarrhea, hyperglycemia due to dexamethasone, and rash due to lenalidomide) * ≥ Grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal supportive therapy * ≥ Grade 4 fatigue persisting \> 7 days * Treatment delay for toxicity \> 21 days Hematologic * Grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 500/mm³) \> 7 days * Febrile neutropenia (ANC \< 1,000/mm³ with fever ≥ 38.3ºC) * Grade 4 thrombocytopenia (platelets \< 25,000/mm³) for \> 7 days despite holding treatment, or Grade 3 or 4 thrombocytopenia associated with bleeding * Treatment delay for toxicity \> 21 days. The maximum-tolerated dose was defined as the dose level below which a drug-related DLT was observed in ≥ 33% of participants in a cohort.
Time frame: Cycle 1, 28 days
This was an open-label study of carfilzomib (CFZ) given in combination with lenalidomide (LEN) and low-dose dexamethasone (DEX) in patients with relapsed multiple myeloma. The study consisted of a dose-escalation portion and an expansion portion. Participants were treated until disease progression (PD) or unacceptable toxicity.
| Milestone | 1: CFZ 15 mg/m² + LEN 10 mg | 2: CFZ 15 mg/m² + LEN 15 mg | 3: CFZ 15 mg/m² + LEN 20 mg | 4: CFZ 20 mg/m² + LEN 20 mg | 5: CFZ 20 mg/m² + LEN 25 mg | 6: CFZ 20/27 mg/m² + LEN 25 mg | 7: CFZ 20/27 mg/m² + LEN 25 mg |
|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 8 | 6 | 6 | 8 | 44 |
| Completed | 6 | 3 | 6 | 4 | 1 | 6 | 20 |
| Not completed | 0 | 3 | 2 | 2 | 5 | 2 | 24 |
| Withdrew: Adverse event | 0 | 1 | 1 | 2 | 1 | 2 | 10 |
| Withdrew: Other | 0 | 0 | 1 | 0 | 3 | 0 | 13 |
| Withdrew: Withdrew consent | 0 | 2 | 0 | 0 | 1 | 0 | 1 |
Treatment-related are those AEs with possible or probable relationship to carfilzomib, lenalidomide or dexamethasone as assessed by the Investigator. The severity of each adverse event was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0, per the following: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Serious adverse events were defined as AEs meeting one of the following: death, life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect in the offspring of an exposed participant, important medical events that may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above, or pregnancy or suspected pregnancy.
| participants | 1: CFZ 15 mg/m² + LEN 10 mg | 2: CFZ 15 mg/m² + LEN 15 mg | 3: CFZ 15 mg/m² + LEN 20 mg | 4: CFZ 20 mg/m² + LEN 20 mg | 5: CFZ 20 mg/m² + LEN 25 mg | 6: CFZ 20/27 mg/m² + LEN 25 mg | 7: CFZ 20/27 mg/m² + LEN 25 mg |
|---|---|---|---|---|---|---|---|
| Any adverse event | 6 | 6 | 8 | 6 | 6 | 8 | 44 |
| Treatment-related adverse event | 4 | 5 | 8 | 4 | 6 | 8 | 43 |
| Grade 3 or higher adverse event | 5 | 6 | 8 | 6 | 6 | 8 | 41 |
| Treatment-related Grade 3 or higher adverse event | 1 | 4 | 7 | 4 | 6 | 8 | 38 |
| Serious adverse event | 3 | 3 | 4 | 4 | 3 | 6 | 22 |
| AE leading to discontinuation of any study drug | 1 | 1 | 3 | 4 | 2 | 3 | 18 |
| AE leading to discontinuation of carfilzomib | 0 | 0 | 1 | 2 | 1 | 1 | 9 |
| Deaths within 30 days of last dose of study drug | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
Dose-limiting toxicity was defined as any of the following events assessed as related to carfilzomib, lenalidomide, or dexamethasone: Nonhematologic * ≥ Grade 2 neuropathy with pain * ≥ Grade 3 nonhematologic toxicity (excluding nausea, vomiting, diarrhea, hyperglycemia due to dexamethasone, and rash due to lenalidomide) * ≥ Grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal supportive therapy * ≥ Grade 4 fatigue persisting \> 7 days * Treatment delay for toxicity \> 21 days Hematologic * Grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 500/mm³) \> 7 days * Febrile neutropenia (ANC \< 1,000/mm³ with fever ≥ 38.3ºC) * Grade 4 thrombocytopenia (platelets \< 25,000/mm³) for \> 7 days despite holding treatment, or Grade 3 or 4 thrombocytopenia associated with bleeding * Treatment delay for toxicity \> 21 days. The maximum-tolerated dose was defined as the dose level below which a drug-related DLT was observed in ≥ 33% of participants in a cohort.
| participants | 1: CFZ 15 mg/m² + LEN 10 mg | 2: CFZ 15 mg/m² + LEN 15 mg | 3: CFZ 15 mg/m² + LEN 20 mg | 4: CFZ 20 mg/m² + LEN 20 mg | 5: CFZ 20 mg/m² + LEN 25 mg | 6: CFZ 20/27 mg/m² + LEN 25 mg |
|---|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities | 0 | 0 | 0 | 0 | 0 | 1 |
Collected over From the first dose of study drug until 30 days after the last dose; 1 to 52 months, with an average of 12 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1: CFZ 15 mg/m² + LEN 10 mg | — | 3/6 (50%) | 6/6 (100%) |
| 2: CFZ 15 mg/m² + LEN 15 mg | — | 3/6 (50%) | 6/6 (100%) |
| 3: CFZ 15 mg/m² + LEN 20 mg | — | 4/8 (50%) | 8/8 (100%) |
| 4: CFZ 20 mg/m² + LEN 20 mg | — | 4/6 (66.7%) | 6/6 (100%) |
| 5: CFZ 20 mg/m² + LEN 25 mg | — | 3/6 (50%) | 6/6 (100%) |
| 6: CFZ 20/27 mg/m² + LEN 25 mg | — | 6/8 (75%) | 8/8 (100%) |
| 7: CFZ 20/27 mg/m² + LEN 25 mg | — | 22/44 (50%) | 42/44 (95.5%) |
| Event | 1: CFZ 15 mg/m² + LEN 10 mg | 2: CFZ 15 mg/m² + LEN 15 mg | 3: CFZ 15 mg/m² + LEN 20 mg | 4: CFZ 20 mg/m² + LEN 20 mg | 5: CFZ 20 mg/m² + LEN 25 mg | 6: CFZ 20/27 mg/m² + LEN 25 mg | 7: CFZ 20/27 mg/m² + LEN 25 mg |
|---|---|---|---|---|---|---|---|
| Disease progressionGeneral disorders | 2/6 | 0/6 | 0/8 | 0/6 | 0/6 | 0/8 | 1/44 |
| PyrexiaGeneral disorders | 0/6 | 0/6 | 2/8 | 0/6 | 0/6 | 0/8 | 1/44 |
| InfluenzaInfections and infestations | 0/6 | 0/6 | 0/8 | 1/6 | 0/6 | 2/8 | 0/44 |
| PneumoniaInfections and infestations | 0/6 | 1/6 | 0/8 | 1/6 | 0/6 | 2/8 | 3/44 |
| BradycardiaCardiac disorders | 0/6 | 0/6 | 0/8 | 0/6 | 1/6 | 0/8 | 0/44 |
| Sick sinus syndromeCardiac disorders | 0/6 | 1/6 | 0/8 | 0/6 | 0/6 | 0/8 | 0/44 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/6 | 0/8 | 1/6 | 0/6 | 0/8 | 0/44 |
| Small intestinal obstructionGastrointestinal disorders | 0/6 | 0/6 | 0/8 | 0/6 | 1/6 | 0/8 | 0/44 |
| PainGeneral disorders | 0/6 | 1/6 | 0/8 | 0/6 | 0/6 | 0/8 | 0/44 |
| CellulitisInfections and infestations | 1/6 | 0/6 | 0/8 | 0/6 | 0/6 | 0/8 | 0/44 |
| Event | 1: CFZ 15 mg/m² + LEN 10 mg | 2: CFZ 15 mg/m² + LEN 15 mg | 3: CFZ 15 mg/m² + LEN 20 mg | 4: CFZ 20 mg/m² + LEN 20 mg | 5: CFZ 20 mg/m² + LEN 25 mg | 6: CFZ 20/27 mg/m² + LEN 25 mg | 7: CFZ 20/27 mg/m² + LEN 25 mg |
|---|---|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 4/6 | 4/6 | 4/8 | 2/6 | 5/6 | 3/8 | 16/44 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/6 | 5/6 | 3/8 | 2/6 | 3/6 | 4/8 | 17/44 |
| AnaemiaBlood and lymphatic system disorders | 2/6 | 2/6 | 6/8 | 2/6 | 3/6 | 3/8 | 14/44 |
| FatigueGeneral disorders | 3/6 | 4/6 | 5/8 | 3/6 | 4/6 | 6/8 | 30/44 |
| DiarrhoeaGastrointestinal disorders | 3/6 | 3/6 | 3/8 | 3/6 | 4/6 | 4/8 | 26/44 |
| Oedema peripheralGeneral disorders | 0/6 | 4/6 | 2/8 | 0/6 | 3/6 | 2/8 | 17/44 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/6 | 4/6 | 4/8 | 1/6 | 1/6 | 3/8 | 17/44 |
| LymphopeniaBlood and lymphatic system disorders | 1/6 | 3/6 | 2/8 | 1/6 | 0/6 | 5/8 | 22/44 |
| PyrexiaGeneral disorders | 0/6 | 1/6 | 5/8 | 3/6 | 1/6 | 4/8 | 19/44 |
| LeukopeniaBlood and lymphatic system disorders | 0/6 | 3/6 | 1/8 | 1/6 | 1/6 | 2/8 | 9/44 |
| Age, Continuous(years) | 1: CFZ 15 mg/m² + LEN 10 mg | 2: CFZ 15 mg/m² + LEN 15 mg | 3: CFZ 15 mg/m² + LEN 20 mg | 4: CFZ 20 mg/m² + LEN 20 mg | 5: CFZ 20 mg/m² + LEN 25 mg | 6: CFZ 20/27 mg/m² + LEN 25 mg | 7: CFZ 20/27 mg/m² + LEN 25 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 64.7 ± 6.65 | 64.2 ± 12.11 | 55.4 ± 7.74 | 61.7 ± 6.68 | 57.7 ± 9.31 | 65.4 ± 7.85 | 62.4 ± 10.75 | 61.9 ± 9.86 |
| Sex: Female, Male(Participants) | 1: CFZ 15 mg/m² + LEN 10 mg | 2: CFZ 15 mg/m² + LEN 15 mg | 3: CFZ 15 mg/m² + LEN 20 mg | 4: CFZ 20 mg/m² + LEN 20 mg | 5: CFZ 20 mg/m² + LEN 25 mg | 6: CFZ 20/27 mg/m² + LEN 25 mg | 7: CFZ 20/27 mg/m² + LEN 25 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 1 | 4 | 3 | 4 | 3 | 3 | 18 | 36 |
| Male | 5 | 2 | 5 | 2 | 3 | 5 | 26 | 48 |
| Race/Ethnicity, Customized(participants) | 1: CFZ 15 mg/m² + LEN 10 mg | 2: CFZ 15 mg/m² + LEN 15 mg | 3: CFZ 15 mg/m² + LEN 20 mg | 4: CFZ 20 mg/m² + LEN 20 mg | 5: CFZ 20 mg/m² + LEN 25 mg | 6: CFZ 20/27 mg/m² + LEN 25 mg | 7: CFZ 20/27 mg/m² + LEN 25 mg | Total |
|---|---|---|---|---|---|---|---|---|
| African American | 0 | 2 | 1 | 2 | 1 | 0 | 3 | 9 |
| Asian/Pacific Islander | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 3 |
| Caucasian | 6 | 3 | 7 | 2 | 5 | 7 | 34 | 64 |
| Hispanic | 0 | 0 | 0 | 2 | 0 | 1 | 4 | 7 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | 1: CFZ 15 mg/m² + LEN 10 mg | 2: CFZ 15 mg/m² + LEN 15 mg | 3: CFZ 15 mg/m² + LEN 20 mg | 4: CFZ 20 mg/m² + LEN 20 mg | 5: CFZ 20 mg/m² + LEN 25 mg | 6: CFZ 20/27 mg/m² + LEN 25 mg | 7: CFZ 20/27 mg/m² + LEN 25 mg | Total |
|---|---|---|---|---|---|---|---|---|
| 0 (Fully active) | 2 | 0 | 3 | 1 | 2 | 2 | 23 | 33 |
| 1 (Restrictive but ambulatory) | 4 | 5 | 5 | 5 | 4 | 6 | 17 | 46 |
| 2 (Ambulatory but unable to work) | 0 | 1 | 0 | 0 | 0 | 0 | 4 | 5 |
| Time Since Diagnosis(years) | 1: CFZ 15 mg/m² + LEN 10 mg | 2: CFZ 15 mg/m² + LEN 15 mg | 3: CFZ 15 mg/m² + LEN 20 mg | 4: CFZ 20 mg/m² + LEN 20 mg | 5: CFZ 20 mg/m² + LEN 25 mg | 6: CFZ 20/27 mg/m² + LEN 25 mg | 7: CFZ 20/27 mg/m² + LEN 25 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Median | 3.3 (2 to 4) | 2.4 (2 to 5) | 3.9 (2 to 15) | 2.8 (0 to 9) | 3.5 (1 to 22) | 4.3 (1 to 12) | 2.8 (0 to 16) | 3.1 (0 to 22) |
The record gives a start of May 2008, a primary completion of May 2013 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Carfilzomib